Last reviewed · How we verify

NCT03903653: ChemoCast

Botulinum Toxin A & Weekly Serial Casting in ABI Inpatients With Lower Extremity Spasticity

Withdrawn Phase 2 Last updated 28 September 2023
What this trial tests

Phase 2 trial testing Botulinum toxin type A in Spastic Foot. Withdrawn.

Timeline
1 September 2019
Primary endpoint
1 November 2019
1 December 2019

Quick facts

Lead sponsorHamilton Health Sciences Corporation
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Start date1 September 2019
Primary completion1 November 2019
Estimated completion1 December 2019

Drugs / interventions tested

Conditions studied

Sponsor

Hamilton Health Sciences Corporation — full company profile →

Who can join

Eligibility, any sex, with Spastic Foot. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effects of Chemodenervation (Botulinum Toxin A) and Serial Casting vs Botulinum Toxin A and without serial casting in Lower Limb Spasticity following ABI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Botulinum toxin type A

Trials testing the same drug.

Other recruiting trials for Spastic Foot

Currently open trials in the same condition.

Other Hamilton Health Sciences Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03903653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing